ClinicalTrials.gg
RecruitingNCT07601867DAPA-RV-CABGUpdated Nov 19, 2026

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

An observational study in Heart Failure and Coronary Arterial Disease, sponsored by Pyatigorsk City Clinical Hospital Number 1. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Pyatigorsk City Clinical Hospital Number 1 · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
72
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Heart Failure with a site in Russia — 9 open to participants now, 10 under way, none of them phase 3. Heart Failure · Russia.

Planned enrollment
9th of 10
72 · median 250
Started
2026
with 2 others
Observational
10 of 25
6 open now
Registered
25th of 25
by date

Among the 25 studies in Heart Failure with a site in Russia, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2026, is one of 10 observational ones, and was the 25th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 25 studies in Heart Failure with a site in Russia are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Failure with a site in Russia, or all of them as a file.
02

Study summary

This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).

Read the detailed description

Patients undergo echocardiography at three time points: pre-operatively (T0), at 1 month post-surgery before dapagliflozin initiation (T1), and at 7 months post-surgery after 6 months of dapagliflozin 10 mg/day (T2).

The primary objective is to evaluate the change in the TAPSE/PASP ratio from T1 to T2.

Secondary objectives are to evaluate changes from T1 to T2 in:

  • Pulmonary artery systolic pressure (PASP)
  • Pulmonary vascular resistance (PVR)
  • Right ventricular fractional area change (RV FAC)
  • Left ventricular ejection fraction (LVEF)
  • NT-proBNP levels
  • Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) overall summary score

The study aims to provide mechanistic insight into the effects of SGLT2 inhibition on right ventricular-pulmonary artery coupling after off-pump coronary artery bypass grafting.

03

Conditions studied

  • Heart Failure
  • Coronary Arterial Disease

Browse trials for

Keywords

  • OPCAB
  • Right Ventricle
  • SGLT2 inhibitor
  • Dapagliflozin
  • TAPSE/PASP
  • Pulmonary vascular resistance
  • KCCQ-23
  • CABG
  • RV-PA coupling
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with LVEF below 50% undergoing elective isolated off-pump coronary artery bypass grafting at a single center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Elective isolated off-pump coronary artery bypass grafting (OPCAB)
  • (LVEF) \< 50% documented on pre-operative echocardiography
  • Written

Exclusion criteria

Exclusion Criteria:

  • Concomitant valve surgery
  • Emergency or urgent CABG
  • Conversion to on-pump during surgery
  • Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI)
  • Cardiogenic shock
  • More than moderate valvular heart disease
  • Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination)
  • Previous CABG or any prior cardiac surgery
  • Severe chronic kidney disease ( \< 25 mL/min/1.73 m²)
  • to SGLT2 inhibitors
  • Inability to obtain adequate echocardiographic windows
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
72 participants (estimated)
Patient registry
No

Groups and cohorts

  • Dapagliflozin Group

    Patients receiving dapagliflozin 10 mg once daily starting at 1 month after off-pump CABG

06

What researchers measure

Primary outcomes

  1. Change in TAPSE/PASP Ratio

    The change in the ratio of tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery pressure (PASP) from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day)

Secondary outcomes

  1. Change in Pulmonary Artery Systolic Pressure (PASP)

    The change in pulmonary artery systolic pressure (PASP) calculated as 4 x (TR Vmax)˄2 + estimated right atrial pressure (RAP) from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin)

  2. Change in Pulmonary Vascular Resistance (PVR)

    The change in pulmonary vascular resistance (PVR) calculated as (TR Vmax / VTI RVOT) x 10 + 0.16 (wood units) from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin)

  3. Change in NT-proBNP Levels

    The change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (pg/ml) from 1 month after surgery (before dapagliflozin) to 7 month after surgery (after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin)

  4. Change in Quality of Life (KCCQ-23 Overall Summary Score)

    The change in qulity of life assessed by the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) Overall Summary Score (range 0 to 100), higher score indicates better quality of life) from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin)

  5. Change in Right Ventricular Fractional Area Change (RV FAC)

    The change in right ventricular fractional area change (RV FAC) calculated as (RVEDA - RVESA) / RVEDA x 100 (%) from 1 month after surgery (before dapagliflozin) to 7 months after surgery ( after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin)

  6. Change in Left Ventricular Ejection Fraction (LVEF)

    The change in left ventricular ejection fraction (LVEF) calculated by biplane Simpson method (%) from 1 month after surgery (befiore dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day)

    Time frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin)

07

Study locations

1 of 1 sites recruiting
  • Pyatigorsk City Clinical Hospital Number 1
    Pyatigorsk, Stavropol Kray 357500, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data will be available upon reasonable request to the Principal Investigator after study completion and publication

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2028, 22 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 22 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 22, 2026
StartActual
Jul 1, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
Jul 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07601867
Lead sponsor
Pyatigorsk City Clinical Hospital Number 1
Responsible party
Samson Badalyan (Cardiologist, Principal Investigator, Pyatigorsk City Clinical Hospital Number 1) — Principal investigator
First posted
May 22, 2026
Start date
Jul 1, 2026
Primary completion
May 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Samson S. Badalyan, MD, PhD
Contact
sambadalyan@mail.ru
+79614972949
Syune V. Markosyan, MD.
Contact
ssm8883@gmail.com
+79633876510
Samson S. Badalyan, MD, PhD
principal investigator · Pyatigorsk City Clinical Hospital Number 1

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion